Hosted by bioaccess® CEO, Julio G. Martinez-Clark, the Global Trial Accelerators™ podcast delivers actionable insights for Medtech, Biopharma, and Radiopharma innovators battling lengthy timelines and costly delays. Each episode features candid conversations with clinical trial pioneers, regulatory strategists, and startup founders who’ve slashed 6–12 months off approvals by leveraging emerging regions like Latin America, Eastern Europe, and Australia. What You’ll Learn: Speed Secrets: How to secure ethics approval in 4–6 weeks (vs. 6+ months in US/EU) using harmonized pathways like MINSA (Panama), ALIMS (Serbia), and Australia’s CTN. Cost-to-Speed Hacks: Operational strategies to reduce trial budgets by 30% while maintaining FDA/EMA compliance. Global Patient Access: Leverage treatment-naive populations in cardiology, rare diseases, and advanced therapies across 50+ pre-vetted sites. Why Listen? <ul
Pitch Analysis
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Public web form
Booking probability
34%
Guest openness
Selective
80/100
Required Score
Sign up to generate a grounded pitch for Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere.
What is Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere?
Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere is a business podcast hosted by Julio G. Martinez-Clark, with 134 episodes on record and a Required Pod Score of 80.
About the host
Julio G. Martinez-Clark hosts Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere, a business show with 134 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #140
Gennaro Maida, CEO and Founder at Bluestocking Health, LLC
Oct 2, 202653 minS2
Episode 140: Gennaro Maida – From Wearable Sensors to Clinical Evidence In this episode, we speak with Gennaro Maida , a healthcare technology executive working at the intersection of wearable technology, clinical research, and artificial intelligence. Gennaro is CEO/CMIO of Denovo Innovations Group, Director of Clinical Products at Tactical Rehabilitation, and recently served as CMIO of The Cena Group. He also serves on the American Heart Association's Health Tech Advisory Group. Our conversation explores how sensor data can be transformed into meaningful clinical evidence, including PPG and HRV signal processing, HIPAA-compliant remote data capture for multi-site studies, and AI architectures designed to support clinical and regulatory evidence. Gennaro also discusses the challenges surrounding digital biomarkers, the importance of establishing "ground truth," and why AI-generated inferences must remain distinct from validated clinical facts. He holds a BME from Duke University and an MS in Medicine from Hahnemann University, with a focus on cardiac surgery outcomes.
Benjamin Holmes, Chief Executive Officer at Nanochon
Sep 25, 20261 hourS2
Dr. Ben Holmes: 3D Printing, MedTech, and the Future of Joint Repair In this episode, we speak with Dr. Ben Holmes , CEO and Co-Founder of Nanochon , a medical technology company developing Chondrograft™ , a 3D-printed synthetic implant designed to repair damaged cartilage and restore joint function for patients who are not yet candidates for knee replacement. Dr. Holmes holds a Ph.D. in Biomedical Engineering from The George Washington University and a B.S. in Mechanical and Aerospace Engineering from the University of Virginia. His research has focused on biomaterials and 3D printing for orthopedic tissue repair. Since co-founding Nanochon in 2016, Dr. Holmes has helped secure nearly $12 million in funding through NSF grants, venture capital, and other awards. He has also guided the company to its first-in-human clinical trial. As a published researcher, patent holder, entrepreneur, and healthcare innovator, Dr. Holmes offers a unique perspective on the journey from biomedical research and engineering to the development and clinical evaluation of medical devices. In this conversation, we discuss the science behind 3D-printed orthopedic implants, the challenges of developing innovative medical devices, the realities of funding a medtech startup, and the potential of advanced manufacturing and biomaterials to transform patient care.
Allison Komiyama, CEO and Founder at Bluestocking Health, LLC
Sep 17, 202649 minS2
In this episode, we are joined by Allison Komiyama, Founder of Bluestocking Health, for a conversation about medical devices, regulatory strategy, clinical evidence, and the journey of bringing innovative medical technologies to market. Allison has spent most of her career helping medical device companies navigate the regulatory process and successfully bring their technologies to market. Over the past seventeen years, she has been involved in hundreds of FDA pre-submissions and premarket submissions covering a wide range of medical device technologies. Her career includes serving as an FDA reviewer in the Center for Devices and Radiological Health (CDRH), as well as founding AcKnowledge Regulatory Strategies, LLC in 2014. Following its acquisition in 2021, Allison continued working with medical device companies of all sizes and across different device types throughout the product life cycle. In 2025, she founded Bluestocking Health with the goal of creating more conversations around medical devices, science, clinical evidence, and healthcare, while helping innovative technologies communicate their value and ultimately improve people's lives. Allison holds a degree in Molecular & Cell Biology from the University of California, Berkeley, and a doctorate in Neuroscience from Stanford University. She also earned her Regulatory Affairs Certification (US) in 2014 and became a RAPS Fellow in 2024. In this conversation, Allison shares her experience and insights into the medical device industry, FDA regulatory pathways, clinical evidence, and the importance of communicating the value of MedTech innovation. Listen to the full episode to learn more about the intersection of science, regulation, and medical technology.
Daniel Zequeto, Founder & CEO at ODC Life Sciences
Sep 10, 202649 minS2
In this episode, we speak with Daniel Zequeto , founder of ODC Life Sciences, about the challenges and opportunities of conducting clinical development across Brazil and Latin America. With more than 20 years of experience as a commercial and clinical leader at Abbott, Hospira, Shire, and Alexion, Daniel has worked on both sides of the equation and witnessed firsthand the challenges sponsors face when entering LATAM without the right local infrastructure. Daniel shares his perspective on clinical development, early access, and patient recruitment, with a particular focus on rare diseases, hematology, oncology, nephrology, and neurology. We also explore what biotech companies and pharmaceutical sponsors need to consider when expanding clinical programs into Latin America and how the right local expertise can make a difference in execution and patient recruitment. Daniel Zequeto is the founder of ODC Life Sciences, a specialized clinical execution partner supporting biotech and specialty pharma companies across Brazil and Latin America. Learn more at odclifesciences.com.
Satabhisa Mukhopadhyay, Founder & Chief Scientist at 4D Path Inc
Sep 4, 202650 minS2
In this episode, we speak with Dr. Satabhisa Mukhopadhyay , Co-Founder and Chief Scientific Officer of 4D Path and co-inventor of its QPOR™ technology. Dr. Mukhopadhyay discusses her journey from theoretical physics and applied mathematics to cancer systems biology, bioinformatics, and AI/ML. We explore how physics-informed algorithms and computational approaches can transform complex biological data into actionable insights for personalized cancer treatment. She also shares insights into 4D Path’s clinical trials, predictive diagnostic technologies, regulatory strategy, and the challenges of translating AI-driven innovation into real-world cancer care.
Every question we get asked before someone starts their trial.
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
What is the difference between Founder Solo and Founder Pro?
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
How do agency tiers work?
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
What is a talent profile?
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Can I switch plans later?
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Do you offer a free trial?
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
What happens if I cancel?
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Is the 20% annual discount automatic?
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
What if I have more than 50 profiles or 20 clients?
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
